Targeting KRAS in cancer
A Singhal, BT Li, EM O'Reilly - Nature Medicine, 2024 - nature.com
RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …
pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations …
Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer
Activating KRAS mutations (KRAS*) in pancreatic ductal adenocarcinoma (PDAC) drive
anabolic metabolism and support tumor maintenance. KRAS* inhibitors show initial …
anabolic metabolism and support tumor maintenance. KRAS* inhibitors show initial …
A ferroptosis amplifier based on triple-enhanced lipid peroxides accumulation strategy for effective pancreatic cancer therapy
M Chen, X Tong, Y Sun, C Dong, C Li, C Wang… - Biomaterials, 2024 - Elsevier
As an iron dependent regulatory cell death process driven by excessive lipid peroxides
(LPO), ferroptosis is recognized as a powerful weapon for pancreatic cancer (PC) therapy …
(LPO), ferroptosis is recognized as a powerful weapon for pancreatic cancer (PC) therapy …
Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment
SA Long, AM Amparo, G Goodhart, S Ahmad… - Frontiers in …, 2024 - frontiersin.org
Despite significant advancements in the treatment of other cancers, pancreatic ductal
adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of …
adenocarcinoma (PDAC) remains one of the world's deadliest cancers. More than 90% of …
[HTML][HTML] Multi-omics pan-cancer study of SPTBN2 and its value as a potential therapeutic target in pancreatic cancer
H Chang, H Chen, T Ma, K Ma, Y Li, L Suo, X Liang… - Scientific Reports, 2024 - nature.com
SPTBN2 is a protein-coding gene that is closely related to the development of malignant
tumors. However, its prognostic value and biological function in pan-cancer, especially …
tumors. However, its prognostic value and biological function in pan-cancer, especially …
[HTML][HTML] Development of Highly Sensitive Anti-Mouse HER2 Monoclonal Antibodies for Flow Cytometry
T Ouchida, H Suzuki, T Tanaka, MK Kaneko… - International Journal of …, 2023 - mdpi.com
Overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer is an
important target of monoclonal antibody (mAb) therapy such as trastuzumab. Due to the …
important target of monoclonal antibody (mAb) therapy such as trastuzumab. Due to the …
[HTML][HTML] Targeting KRAS in pancreatic cancer
S Stickler, B Rath, G Hamilton - Oncology Research, 2024 - ncbi.nlm.nih.gov
Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient
therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all …
therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all …
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
SJ Reshkin, RA Cardone, T Koltai - Cells, 2024 - mdpi.com
Pancreatic cancer is a highly lethal disease with a 5-year survival rate of around 11–12%.
Surgery, being the treatment of choice, is only possible in 20% of symptomatic patients. The …
Surgery, being the treatment of choice, is only possible in 20% of symptomatic patients. The …
Inhibition of GTPase KRASG12D: a review of patent literature
Y Li, L Yang, X Li, X Zhang - Expert Opinion on Therapeutic Patents, 2024 - Taylor & Francis
Introduction KRAS is a critical oncogenic protein intricately involved in tumor progression,
and the difficulty in targeting KRAS has led it to be classified as an 'undruggable …
and the difficulty in targeting KRAS has led it to be classified as an 'undruggable …